

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

DELAY IN DESPATCH OF CIRCULAR

The Company announces that, as additional time is required for the Company to finalise certain information in the Circular, it is expected that the date of despatch of the Circular will be postponed from 15 March 2019 to a day falling on or before 12 April 2019.

Reference is made to the announcement of Tianda Pharmaceuticals Limited (the Company) dated 22 February 2019 (the Announcement) in relation to, among other things, the disposal of 100% equity interest of a wholly-owned subsidiary. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular containing, among others, (i) further details of the Agreement and the Transactions; (ii) the recommendation from the Independent Board Committee to the independent Shareholders in relation to the Agreement and the Transactions; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the independent Shareholders; and (iv) the notice of the EGM, will be despatched to the Shareholders and in accordance with the Listing Rules on or before 15 March 2019 (the Circular).

As additional time is required for the Company to finalise certain information in the Circular, it is expected that the date of despatch of the Circular will be postponed from 15 March 2019 to a day falling on or before 12 April 2019.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 15 March 2019

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. SHEN Bo, Mr. FENG Quanming and Dr. LAM Lee G.; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.